Sai Life Sciences Ltd. Share Price

Sai Life Sciences Ltd. – Company Overview

→ Leading Contract Research, Development and Manufacturing Organization (CRDMO). → Partners with 280+ global pharmaceutical and biotechnology companies. → Specializes in new chemical entity (NCE) small-molecule drug discovery, development and manufacturing. → Expertise across synthetic and medicinal chemistry, biology, DMPK, toxicology and computational chemistry. → Operates across India, the UK, the USA and Japan, with a strong focus on quality and regulatory compliance. → R&D and manufacturing facilities in Hyderabad and Bidar have received USFDA Establishment Inspection Reports (EIRs). Financial & Fundamental Analysis → Operating Revenue: ₹2,250.36 Cr (TTM). → Revenue Growth: 29% annually, indicating strong growth. → Pre-tax Margin: 21%, reflecting healthy profitability. → ROE: 14%, indicating reasonable returns on shareholders’ capital. → Debt-to-Equity: 1%, suggesting low financial leverage. Technical Analysis → Trading close to its 50-day moving average (50 DMA). → Comfortably above its 200-day moving average (200 DMA), approximately 28% higher. → The 50 DMA is a key support level to monitor. → Technical View: Holding support near the 50 DMA could sustain the upward momentum, while a decisive breakdown may indicate near-term weakness. Disclaimer: For informational and educational purposes only. This is not investment advice or a recommendation to buy or sell securities.

See More

Sai Life Sciences: CRO grows 24%, capex cycle begins

Sai Life Sciences Limited (NSE: SAILIFE) started FY27 with Q1 consolidated revenue of ₹554 crore, up 12% YoY. Net profit rose 22% to ₹73 crore. The stock closed at ₹1,541.20 on 1 October, up 70% in 2026. What happened CRO revenue grew 24% YoY, twice the rate of total revenue, and now represents 40% of the business, about ₹222 crore. CDMO, the larger half, contributed 60% or about ₹332 crore. PAT margin improved from 12% to 13%. Discovery revenue reached ₹775 crore in FY26, up 24% from ₹626 crore. Its CMC pipeline has 33 commercial molecules and 14 late-phase molecules. Why it matters Over 65% of discovery customers used multiple services across FY23 to FY26. One top-tier customer expanded its relationship to cover discovery through commercial supply in Q1 FY27. My view The business is cleaner than Jubilant right now. Revenue and profit are both growing. The capex changes that. Sai spent ₹263 crore in Q1 and budgeted ₹1,100 to ₹1,300 crore for FY27. Around 75% goes to CDMO and 25% to CRO. Utilisation was 65%, so demand must catch up. The balance sheet is the reason this is manageable. Sai used IPO proceeds to repay ₹720 crore of debt. Net debt to EBITDA was just 0.04 times in FY26. So it enters this capex cycle in far better shape than before the IPO. Five year profit: ₹6, ₹10, ₹83, ₹170 and ₹349 crore. That is consistent growth. Jefferies maintains a Buy with a ₹1,610 target. At ₹1,541, the stock is 4.5% away. What I am watching Q2 FY27 results, capacity utilisation above 70%, and new peptide and ADC programme wins. On the chart, ₹1,015 is the 52-week low. My stance: Hold. Outstanding business, but priced for perfection. Revisit near ₹1,300. Disclosure: I do not hold a position in Sai Life Sciences Limited at the time of writing. This is not investment advice.

See More

Indegene Ltd to focus on Operationalizing AI

Indegene Ltd Operationalizing AI to Deliver Enterprise Outcomes at Indegene Digital Summit 2026 Key themes that emerged from the presentations and discussions at the summit included a broad-based recognition that operationalizing AI for business impact requires a next generation, life-sciences native operating model powered by domain understanding, experience and context. Beyond operational efficiency, several life sciences leaders pointed out that AI can help connect data, intelligence and evidence to enable strategic decisions, drive successful product launches, deliver more personalized customer experiences and accelerate drug discovery and clinical research. Speaking on the occasion, Manish Gupta, Chairman and CEO, Indegene said, “Life sciences has built an extraordinary legacy of helping people live longer, healthier lives. But increasingly specialized therapies and precision medicines cannot be supported by operating models designed for an era of mass promotion. The opportunity now is to thoughtfully rewire the enterprise around AI, augment our people, and build systems that are smarter, faster, and more responsive, turning the promise of technology into measurable performance for patients, physicians, and the business.” Opinion The news may have positive effect on stock price in Medium Term to Long Term Disclaimer : I do not hold this stock . This is not a buy,sell or hold recommendation

See More

SAIL LIFE SCIENCES LTD – STRONG BULLISH MOMENTUM

Technical View: The stock is currently showing a strong bullish structure, supported by a sustained uptrend and a series of higher highs and higher lows on the chart. The recent price action indicates a breakout above an important resistance zone, reflecting renewed buying interest and improving market sentiment. The stock is also sustaining comfortably above its short-term support area, which is an encouraging sign for the continuation of the prevailing trend. As long as the price holds above the key support levels, the broader bullish structure may remain intact. 🔑 KEY TECHNICAL LEVELS 🟢 Support Zone: ₹1,602–₹1,554 🟢 Key Support: ₹1,554 🔴 Resistance Zone: ₹1,697–₹1,745 🎯 Potential Upside Levels: ₹1,793 | ₹1,840 | ₹1,888+ 📊 Market View: A sustained move above ₹1,697 could strengthen the existing bullish momentum and may support further upside towards the mentioned target zones. The ₹1,697–₹1,745 region remains an important resistance area, and traders should closely observe price action and volume around this zone. On the downside, ₹1,554 remains the key support level. Sustaining above this level would keep the current technical structure positive, while a decisive breakdown below the major support zone could weaken the bullish setup. Traders and investors should consider overall market conditions, price action, volume and their individual risk profile before making any decision. ⚠️ Disclaimer: This content is provided strictly for educational and informational purposes only. It should not be considered a buy/sell recommendation, investment advice, or a solicitation to trade. Please conduct your own research and consult a SEBI-registered investment professional before making any investment decision. — AALGO BREATHS 📊

See More

SAI LIFE SCIENCES Development & Manufacturing

Strengths Strong FY26 growth: Revenue from operations increased 29% YoY to ₹2,192 Cr. Sharp profitability improvement: EBITDA increased 56% YoY, while net profit increased 109% YoY in FY26. Integrated CRDMO capabilities across drug discovery, development and commercial manufacturing. Global pharma customer relationships provide opportunities for repeat business and long-term programs. Strong momentum continued into FY26: 9M FY26 revenue grew 43%, EBITDA 79% and PAT 199% YoY. Weaknesses Business requires high investment in facilities, technology and scientific talent. CRDMO revenues can be affected by project timing, customer decisions and development cycles. Dependence on global pharmaceutical customers exposes the company to changes in outsourcing budgets. Expansion and capacity investments can create higher depreciation and fixed-cost pressure if utilization is slower than expected. Opportunities Increasing global pharma outsourcing can support long-term CRO/CDMO demand. Supply-chain diversification away from China creates opportunities for Indian CRDMOs. Expansion of integrated services can increase wallet share from existing customers. Greater participation in complex drug development and commercial manufacturing can improve customer stickiness. Management's focus on deepening relationships with large pharma customers provides a potential growth runway. Threats Global competition from established CRO/CDMO players. Regulatory and compliance risks across multiple international markets. Delays or cancellations in customers' drug-development programs. Pricing pressure from customers can affect margins. Currency movements and changes in global pharmaceutical spending can influence results.

See More

Sai Life Sciences: Scaling Peptide Capabilities

is actively aligning capital expenditure to target high-growth modalities, including macrocyclic peptides, Peptide-Drug Conjugates (PDCs), and radiochemistry. It is launching a dedicated peptide development lab for a top-tier pharmaceutical partner, extending its center of excellence support, and planning an operational peptide manufacturing plant near Hyderabad by 2028. Aggressive Capacity Expansion: The company plans to deploy ₹1,100–1,300 crore in FY27, devoting 75% to CDMO operations and the remainder to discovery capabilities like AI. Manufacturing capacity will expand from 700 KL to 1,150 KL, starting with a 225-KL block in Q3 FY27. Additionally, new formulation capacity will cater to clinical trials up to Phase 2 under China+1 strategies. FTE Model Replicating Industry Best Practices: Utilizing the Full-Time Equivalent (FTE) model—similar to WuXi AppTec—the firm secures dedicated resource contracts for 65% of its engagements. Over the past 15 months, this framework helped convert pilot programs into long-term commercial relationships and added six late-phase molecules to its development pipeline. Accelerating Clinical Pipeline Visibility: Near-term earnings visibility is bolstered by a growing Phase 3 portfolio. One customer secured regulatory approval last fiscal year, two reach milestones in FY27, and another is expected in Q2 FY28, providing steady long-term commercial supply streams. Strong Revenue Growth with Premium Valuations: While Q1 FY27 revenue grew 12% year-over-year (led by a 26% surge in discovery services), performance slightly trailed guidance. Top-line momentum is projected to accelerate in H2 FY27. However, with the stock rallying over 70% YTD to trade at 37x EV/EBITDA FY28e, valuations fully reflect this medium-term growth.

See More